ELTP News Alert Elite Pharma Inc (ELTP) 0.3295 11/18/2014 20

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 9:55 PM

Elite Pharma Inc (ELTP) 0.3295 $ELTP

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, November 19, 2014 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.

Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.

OTC Daily Trading News: Evoq Properties, Inc. MedBox, Inc. LabStyle Innovations Corp, MyEcheck, Inc. Elite Pharmaceuticals, Inc.
PR Newswire Europe - Tue Aug 19, 10:11AM CDT
LONDON, August 19, 2014 /PRNewswire/ --

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
GlobeNewswire - Thu Aug 14, 3:14PM CDT
Revenues Increase by 61%, Product Development on Schedule

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
GlobeNewswire - Wed Aug 13, 6:09AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide a quarterly business update at 11:00 AM ET on Monday, August 18, 2014. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals reports launch of pivotal bioequivalence study of ELI-201 in healthy volunteers to address issues in prescription drug abuse
M2 - Wed Jul 16, 9:08AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) disclosed on Tuesday the dosing of the first volunteer in a pivotal bioequivalence study of ELI-201 utilising its proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
GlobeNewswire - Tue Jul 15, 10:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating

Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer.

OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.

Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.

Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY
FEYE: 31.87 (-0.45), AMAT: 22.68 (+0.20), KEY: 13.31 (+0.07)

Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FL Technics Indonesia Expands with EASA Certification

Bali's Skies Just Got a Major Upgrade Picture this: You've got a sprawling 17,000 square meter facility sitting pretty at I Gusti Ngurah Rai International Airport, nestled in the paradise locale of Bali. What's next? It's now flexing some serious muscles with its newfound EASA Part-145 certification, allowing it to tackle aircraft registered in the European Union. This is...

Zinzino Eyes European Market With New Botanical Line

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

111, Inc. Strategizes with Advisors Amid Proposal Talks

Every time a company's board starts tossing around phrases like "strategic alternatives," you’ve got to pay closer attention. 111, Inc., holding the NASDAQ ticker YI, is one such entity at a crossroads. They've enlisted Houlihan Lokey China Limited as their independent financial advisor and Kirkland & Ellis as their U.S. legal counsel to sift through potential strategic...

Redwood and SAP Partner on Secure File Transfer

Redwood Advances SAP Interiors with New File Solution October 26, '26 is now a landmark for Redwood Software. They've just rolled out their SAP Managed File Transfer solution. Got the brainpower behind Redwood and SAP operating together here, and they're offering this to enterprises aimed at optimizing their file-based workflow. If you're scratching your head just hearing...

Electra's Ultra Short Aircraft Revolutionizes Air Travel

From Tarmacs to Heliports: A New Era in Air Travel The aviation world doesn’t often see a sea change, but when a fixed-wing flyer touches down at a heliport, it grabs your attention. Electra’s recent leap into Manhattan’s Downtown Skyport highlights a promising shift in regional air mobility, doing away with the age-old reliance on long runways. It’s a shift that...

United Vein Expands Vero Beach Network for Specialized Care

Simplifying Vein Healthcare in Vero Beach Out of all the surprises life throws, leg cramps and bulging veins seem like small potatoes—until they're not. That's why folks in Vero Beach got a new lifeline today with the United Vein & Vascular Centers opening another clinic. At the crossroads of the 37th Street medical district, this place puts specialized vein care right...

Ernesta Expands Southeast Reach with Atlanta Showroom

Ernesta's Southeast Play: The Atlanta Showroom Here's something to turn heads in the world of custom home design—Ernesta has just set up shop in Atlanta, a move that speaks volumes about their ambitions in the Southeast market. This isn't just about selling a few more rugs; it's a calculated step into a region ripe with design potential and a hunger for bespoke home...

Natural Field Reinvents Supplement Delivery at SupplySide

Pioneering New Frontiers in Supplement Delivery Sometimes you can taste the winds of change in your morning coffee, and this time it’s in the world of dietary supplements. SupplySide Global 2026 is shaking up the scene, folks, and Natural Field Co., Ltd. is leading that charge with some pioneering approaches that might just redefine how we gulp our health aids. Beyond...

Elbit Systems Lands $200M APAC ISTAR Contracts

Elbit Systems Secures Major Asia-Pacific Deal You know, it's not every day that a defense contractor like Elbit Systems (NASDAQ:ESLT) bags a $200 million deal in the Asia-Pacific region. A big move in a high-stakes game where technology, strategy, and geography collide. This isn't some random supply deal; this involves the cutting edge of defense tech—ISTAR and training...

Boar's Head Introduces Authentic Italian Ricotta

Boar's Head Brings Verona's Ricotta Stateside Imagine walking into your kitchen and finding a slice of authentic Italy sitting right there on your counter. That's what Boar's Head promises with its introduction of Italian Ricotta All Natural Cheese. It’s not just cheese; it’s a culinary passport straight from Verona, Italy, crafted using traditional techniques that...